Immunome (NASDAQ:IMNM) Price Target Lowered to $21.00 at Piper Sandler

Immunome (NASDAQ:IMNM) had its price target decreased by Piper Sandler from $23.00 to $21.00 in a research report released on Thursday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other equities analysts have also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Stephens assumed coverage on Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Stock Down 11.0 %

Shares of IMNM stock traded down $1.23 during mid-day trading on Thursday, reaching $9.91. The stock had a trading volume of 3,162,245 shares, compared to its average volume of 767,025. The firm’s 50 day simple moving average is $13.19 and its 200 day simple moving average is $13.82. Immunome has a one year low of $6.93 and a one year high of $30.96. The firm has a market cap of $595.14 million, a PE ratio of -1.28 and a beta of 1.82.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative return on equity of 48.36% and a negative net margin of 3,014.59%. The firm had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.62 million. Sell-side analysts forecast that Immunome will post -1.92 earnings per share for the current fiscal year.

Insider Activity at Immunome

In other news, CFO Max Rosett sold 14,380 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at $760,090.76. The trade was a 23.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. raised its position in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares during the period. MetLife Investment Management LLC grew its stake in shares of Immunome by 129.1% during the third quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock worth $442,000 after purchasing an additional 17,053 shares during the period. FMR LLC grew its stake in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after purchasing an additional 13,757 shares during the period. Finally, Cerity Partners LLC grew its stake in shares of Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after purchasing an additional 5,043 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.